Lonza Extends Partnership for Antibody-Drug Conjugates Supply

Lonza Group AG announced the extension of its collaboration with a major biopharmaceutical partner to supply antibody-drug conjugates (ADCs) on a commercial scale. The agreement includes the construction of a bioconjugation suite at Lonza’s Biopark in Visp, Switzerland, to support the manufacturing needs of a new ADC targeting difficult cancers. The new facility, expected to be operational by 2027, will create around 100 jobs.

Lonza will also provide monoclonal antibody (mAb) manufacturing services at its facility in Porriño, Spain. The ADC will be processed in the new Visp suites. This expansion is built on a successful track record of manufacturing bioconjugates and strengthens Lonza's position in the global ADC market.